In vitro and in vivo evaluation of human tumor necrosis factor-α (hTNFα) chemically conjugated to monoclonal antibody

Journal of Drug Targeting

Volumn 5, Issue 2, 1998, Pages 109-120

  Pietersz, Geoffrey A ^a   Toohey, Brendan ^a   McKenzie, Ian F C ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

Immunoconjugate; Localisation; Monoclonal antibody; Tumour access; Tumour necrosis factor

Indexed keywords

T LYMPHOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL STRAIN L 929; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TARGETING; DRUG TUMOR LEVEL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0031896764     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/10611869808995864     Document Type: Article

References (24)

1. Aggarwal B.B., Kohr W.J., Hass P.E., Moffat B., Spencer S.A., Henzel W.J., Bringman T.S., Nedwinge G.E., Goeddel D.V. and Harkins R.N. (1989) Human tumour necrosis factor: production, purification and characterisation. J. Biol. Chem., 260, 2345-2354.
2. Beutler B. and Cerami A. (1989) The biology of cachectin/TNF-a primary mediator of the host response. Annu. Rev. Immunol., 7, 625-655.
3. 125I-containing acylating agent. Biochem. J., pp 529-539.
4. Ey P.L., Prowse S.J. and Jenkin C.R. (1978) Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A Sepharose. Immunochemistry, 15, 429-434.
5. Fruehauf J.P. and Sinha B.K. (1992) Selective formation of tumour necrosis factor-α (TNF) degradation products contributes to TNF mediated cytotoxicity. Oncology Res., 4, 91-101.
6. Gillies S.D., Young D., Lo K-M. and Roberts S. (1993) Biological activity and in vivo clearance of antitumor antibody/ cytokine fusion proteins. Bioconj. Chem., 4, 230-235.
7. Gillies S.D., Young D., Lo K-M., Foley S.F. and Reisfeld R. (1991) Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody. Hybridoma, 10, 347-356.
8. 131I labelled human growth hormone of high specific radioactivity. Biochem. J., 89, 114-123.
9. Hogarth P.M., Edwards J., McKenzie I.F.C., Goding J.W. and Liew F.Y. (1982) Monoclonal antibodies to murine Ly-2.1 cell surface antigen. Immunology, 46, 135-144.
10. Kemeny N., Childs B., Larchian W., Rosado K. and Kelsen D. (1990) A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma. Cancer, 66, 659-663.
11. Kull Jr F.C. and Cuatrecasas P. (1981) Possible requirement of internalization in the mechanism of in vitro cytotoxicity in tumor necrosis factor serum Cancer Res., 41, 4885-4890.
12. Larrick J.W. and Wright S.C. (1990) Cytotoxic mechanism of tumor necrosis factor-α. FASEB J. 4, 3215-3223.
13. McLaughlin P.J., Elwood N.J., Ramadi L.T., Pica M.R. and McKenzie I.F.C. (1990) Improvement in sensitivity of enzyme-linked immunosorbent assay for tumour necrosis factor. Immunol. Cell Biol. 68, 51-55.
14. Pietersz G.A., Kanellos J. and McKenzie I.F.C. (1988) Novel synthesis and in vitro characterisation of disulfide-linked ricin monoclonal antibody conjugates devoid of galactose binding activity. Cancer Res., 48, 4469-4476.
15. Russel S.M., Krauer K.G., McKenzie I.F.C. and Pietersz G.A. (1990) Effect of tumor necrosis factor on the anti-tumor efficacy and toxicity of aminopterin-monoclonal antibody conjugates. Parameters in optimization of therapy. Cancer Res., 50, 6028-6033.
16. Schoenfeld H.J., Poeschl B., Frey J.R., Loetscher H.R., Hunziker W., Lustig A. and Zulauf M. (1991) Efficient purification of recombinant human tumor necrosis factor beta from E. coli yields biologically active protein with a trimeric structure that binds to both tumor necrosis factor receptors. J. Biol. Chem., 266, 3863-3869.
17. Shimomura K., Manda T., Mukumoto S., Kobayashi K., Nakano K. and Mori J. (1988) Recombinant human tumor necrosis factor-α: thrombus formation is a cause of anti-tumor activity. Int. J. Cancer, 41, 243-247.
18. Smyth M.J., Pietersz G.A. and McKenzie I.F.C. (1988) Increased anti-tumor effect of immunoconjugates and tumor necrosis factor in vivo. Cancer Res., 48, 3607-3612.
19. Smyth M.J., Pietersz G.A., Classon B.J. and McKenzie I.F.C. (1986) The specific targeting of chlorambucil to tumours. JNCI, 76, 503-510.
20. Tartaglia L.A., Weber R.F., Figari I.S., Reynolds C., Palladino Jr. M.A. and Goeddel D.V. (1991) The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc. Natl. Acad. Sci. USA, 88, 9292-9296.
21. Van Ostade X., Tavernier J., Prangé T. and Fiers W. (1991) Localization of the active site of human tumour necrosis factor (hTNF) by mutational analysis. Embo J., 10, 827-836.
22. Vilcek J. and Lee T.H. (1991) Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J. Biol. Chem., 266, 7313-7316.
23. Xing P.X., Tjandra J.J., Stacker S.A., Teh J.G., Thompson C.H., McLaughlin P.J. and McKenzie I.F.C. (1989) Monoclonal antibodies reactive with mucin expressed in breast cancer. Immunol. Cell Biol., 67, 183-195.
24. Yang S.D., Moyana T. and Xiang J. (1955) A genetically engineered single-chain Fv/TNF molecule possesses the anti-tumor immunoreactivity of Fv as well as the cytotoxic activity of tumor necrosis factor. Mol. Immunol., 32, 873-881.